BlossomHill and Latigo close IPO week with $496 million raised

BlossomHill Therapeutics, a cancer‑focused biotech, completed its initial public offering this week.

Latigo, a company developing non‑opioid pain treatments, also went public at the same time.

Together the two offerings raised about $496 million, marking the culmination of a busy IPO period that saw four biotech listings.

The capital is expected to fund BlossomHill’s efforts to enter AstraZeneca’s oncology space and to support Latigo’s development of pain medicines competing with Vertex’s non‑opioid candidate.